Agenus Inc【AGEN】株式ニュース

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping...

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision...

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company...

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Combination of Botensilimab/Balstilimab with MiNK Therapeutics’ AgenT-797 Shows Strong Immune Activation and Potential to Enhance Outcomes in...

CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Proffered Papers, Session 2, Session Date and Time of release dated February 12, 2025, should read: Monday, February 24th, 1:39-1:45 p.m. PST...

Form 4 - Statement of changes in beneficial ownership of securities

Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced publication in the Journal of Clinical Oncology showcasing data from its...

Form 4 - Statement of changes in beneficial ownership of securities

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BAL’s potential to...

Form 4 - Statement of changes in beneficial ownership of securities

I tossed a couple of coins in the fountain at $7 wishing for 50% or better

👍️0

DP1011 8月前

Up here. Keep on going!!!

👍️0

jondoeuk 11月前

I expect more dilution is on the way after the R/S. Unless they sell non-strategic assets, which is hardly a sustainable business practice.

👍️0

jondoeuk 11月前

The co-founder/CEO/Chairman has been for 20+ years pumping the company, telling stories and making promises, all the while getting rich off retail.

👍️ 1

jondoeuk 11月前

They are proposing a R/S at a ratio of 1-for-20 https://finance.yahoo.com/news/why-agenus-stock-plummeted-nearly-233805990.html

👍️0

Paullee 1年前

where did you see that ??????

👍️0

TrendTrade2016 1年前

ALL OUT...REVERSE SPLIT ANNOUNCEMENT

👍️0

TrendTrade2016 1年前

AGEN SMALL GAPPER AND ON TARGET TO 1.04

👍️0

DP1011 1年前

Interesting, would be nice to see this back over a dollar.

👍️0

Stumblebum 1年前

Something is cooking …..last week good upward movement and picked up volume 😊

👍️0

TrendTrade2016 1年前

AGEN POPPING HARD TO 1.04

👍️0

axelvento 1年前

A Biologics License Application (BLA) is expected to be submitted to the FDA for metastatic colorectal cancer (CRC) in mid-2024.

Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy

Who knows what does the future hold$$$$$$$

👍️0

Denzel-72 1年前

R/S is coming … money down the drain

TommyBoyTrader9460 1年前

$AGEN
https://x.com/hannahadad8890/status/1741101133777486197?s=61

👍️0

TommyBoyTrader9460 1年前

$AGEN
https://x.com/hannahadad8890/status/1739966219229258048?s=61

👍️0

Doktornolittle 1年前

Admin(s) please erase my post # 1170. I don't think the issues were the fault of B. Riley or ASCO... . Maybe, but it is unclear and not worth having the negativity there for posterity.

... B.Riley psswd is in immediate registration confirmation email. That may not be unusual, but the email subject line gives no indication that it contains a psswd. It gives a warm and fuzzy that your registration did go through, so the reader is not compelled to open the email. The reader already knows they registered and the reader does not yet know that they are going to have to login with a password. May be the usual way to do this, but I don't think it is a good way.

As for ASCO GI. Some say the abstracts were embargoed since late-breaking. Maybe so, but why then did the ASCO website instruct me to login to view the abstract. This is with the abstract already located. This is on the abstract page, which only contains the header at that point. Causes confusion.

👍️0

Doktornolittle 2年前

B Riley would not allow me to view the recent webcast. ASCO would not allow me to view the recently "released: Abstracts. No PR from the company. This while Yhoo Finance is so controlled and filtered since the recent takeover that no light escapes there either.

If you had a similar experience, please message me and we can join forces for a complaint to the SEC.

More detail:
B Riley has no contact other than their private email system which does not work.
ASCO: Found the abstracts, but they told me that I had to log in to view the abstract beyond the header and authors. I spent 12 hours trying to do that. After many dead end phone calls and emails, I finally got them to allow me to log in. Went back to the abstract and now they tell me, you don't have access to the abstract. A slightly different message than when I was not logged in, but still no access.

I videotaped my efforts to access the webcast and abstracts. I suggest you do the same if you have problems like this in the future.

These are SEC violations.

Where is the SEC on these things? I suspect they could care less, but I want to find out.

👍️0

Doktornolittle 2年前

SITC Oral Presentation on BOT w/wo BAL tomorrow with about a thousand authors. It is a brief presentation, but there are only 4 such on schedule and they are the last notes of the entire SITC session. It is likely that everybody at SITC who can get to these final presentations will be there. I am no technical expert in these matters, but I am confident that BOT is a big deal for a couple of reasons beyond the data. 1) In a brief presentation after ASCO, there were major league Cancer experts discussing the presented results. Those experts were truly impressed with this activity against cold tumors. I have seen phony looking presentations by small biotech companies, and this was not that. Of that I am certain and will listen to nobody else's opinion about it. 2) Agenus has been touting BOT for years now. They knew from the beginning that they had something very special. For me it is not a great leap of faith to expect big things from BOT w/wo BAL. No posts here in almost a year. None for months at alter forum IV, and alter other forum just went through a huge change. Suddenly no new posts in the last 24 hours in the middle of SITC? I don't thinks so. So far, I give the facelift at hooya a big thumbs down. This is it guys. Your new home.

👍️ 1

stockguard 3年前

AGEN Agenus initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Michael King initiated coverage of Agenus with a Buy rating and $12 price target. The company has developed a broad portfolio of promising antibodies and bispecifics covering many validated targets in immuno-oncology, King tells investors in a research note. The company has "struck multiple lucrative development agreements with some of the industry's leading oncology players," adds the analyst.

👍️0

north40000 3年前

$11 from $12. Buy rating. Analyst has been switching back and forth between $11 and $12. November date on last PT, per GOOGL search.

👍️0

investtemp 3年前

what was the B Riley target price?

👍️0

stockguard 3年前

B. Riley bullish on Novavax, Agenus amid Omicron spread.
B. Riley analyst Mayank Mamtani reiterates his sector-level view of the need for at least annual vaccine boosters and there being a durable COVID vaccine market, sharing many of the attributes with an expanding flu market that has been clearly rewarding differentiated vaccine solutions. The analyst views sustenance of multiple vaccine modalities prevailing over an "mRNA takes all" viewpoint. Mamtani has a Buy rating and a price target of $305 on Novavax (NVAX) as Omicron variant-specific development preparedness and COV-Boost data reiterate robust positioning in global, durable COVID-19, and flu markets. The analyst also has a Buy rating and a price target on Agenus (AGEN) as he believes under-the-radar SaponiQx's adjuvant is poised to play a meaningful role in strong expected protein subunit vaccine demand. He keeps a Neutral rating on Vaxart (VXRT), calling it one of the few "investable" COVID-19 vaccine pipeline programs directly tackling the transmission issue.

👍️0

stockguard 3年前

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
https://finance.yahoo.com/news/agenus-subsidiary-saponiqx-builds-innovative-113000784.html

👍️0

stockguard 3年前

Will not be in the money until it hits their price, no biggie on this small fry:
SEC Form S-3ASR filed by Agenus Inc.
https://quantisnow.com/insight/2002956?s=s

👍️0

pipette 3年前

There was an article in Oct 26 did u get that one? Most trading platforms have news with their tickers too.

👍️0

malice1 3年前

China just shut down yahoo and aol. I was on the Yahoo Agen Board. Can anyone keep me updated on any significant news?

Either way i`m only focusing on 1181 now and the cash they have on the books to see it through. Market was overly fixated on Bali in cervical which was small niche as even Management suggested.

👍️0

Jnk 3年前

Well I just bought a bunch more shares!! Hope it pays out!!

👍️0

stockguard 3年前

UPDATE: Agenus withdraws cervical cancer application, and a behind the scenes David vs. Big Pharma regulatory battle is revealed
https://www.fiercebiotech.com/biotech/agenus-withdraws-cervical-cancer-application-for-balstilimab-after-fda-fully-authorizes

👍️0

stockguard 3年前

Agenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
https://endpts.com/agenus-calls-out-fda-for-playing-favorites-as-it-pulls-cervical-cancer-bla-at-agencys-request/

👍️0

malice1 3年前

longboarder have any idea what happened the last two days?

👍️0

longboarder7892 4年前

Thank you Dr. Hidalgo for all that you have done here with AGEN in just a few months we went from 2.50 to almost 6.50 and will be helping save lives. I hope your work will do the same for my other company that you are on the board of and the PI of their trial. AGEN is looking great with the BMY investment... mmmm

Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Bristol-Myers Squibb Company (NYSE:BMY) and Agenus Inc. (NASDAQ:AGEN) today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus' proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. AGEN1777 is an Fc-enhanced antibody in late preclinical development designed to target major inhibitory receptors expressed on T and NK cells to improve anti-tumor activity. In preclinical studies this approach has shown significant potential in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective.

* * $AGEN Video Chart 05-18-2021 * *

Link to Video - click here to watch the technical chart video

👍️0

JohnLocke101 4年前

Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+

👍️0

iancnyc 4年前

thank god i heard on
look at that!!!

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

👍️0

iancnyc 4年前

what’s going on with this Turd today?

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Agenus Inc (AGEN)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

AGEN ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Form 4 - Statement of changes in beneficial ownership of securities

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Form 4 - Statement of changes in beneficial ownership of securities

AGEN Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Agenus Inc (AGEN) ニュース

Agenus Inc (AGEN)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

AGEN ニュース

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Form 4 - Statement of changes in beneficial ownership of securities

Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Form 4 - Statement of changes in beneficial ownership of securities

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Form 4 - Statement of changes in beneficial ownership of securities

AGEN Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する